Skip to main content
Top
Published in: Supportive Care in Cancer 1/2012

01-01-2012 | Original Article

Health economics of a palliative care unit for terminal cancer patients: a retrospective cohort study

Authors: Hyun-myung Jung, Jinhyun Kim, Dae Seog Heo, Sun Kyung Baek

Published in: Supportive Care in Cancer | Issue 1/2012

Login to get access

Abstract

Purpose

The objective of this study was to evaluate cost-reduction efficacy of a palliative care unit (PCU) by analyzing medical expenses of terminal cancer patients.

Methods

Hospital bills and medical records of 656 patients who died of cancer from January to December 2007 at one university hospital in Seoul were analyzed.

Results

Of the total 656 patients, 126 died in the PCU. Compared to non-PCU patients, PCU patients were more likely to permit do-not-resuscitate (DNR), visit the emergency room (ER), and receive palliative chemotherapy (P < 0.001, P = 0.045, P = 0.002). The non-PCU patients were admitted to the intensive care unit (ICU), used a ventilator, and received hemodialysis more often (P < 0.001, P < 0.001, P < 0.001). Total medical cost per all patients within 6 months of death averaged $27,863. There was a significant difference in medical costs starting at 2 months before death between PCU and non-PCU patients. The medical cost of the PCU group was 32.8% lower 1 month before death and 33.0% lower 2 months before death than the non-PCU group (P < 0.001, P < 0.001). Patients using PCU services, those with solid cancers, and those with less than a high school education paid lower medical expenses (P < 0.05)

Conclusion

Cost savings of the PCU were verified. It was also determined that specific factors were tied to increased medical expenses during the last 6 months of life. If these parameters are controlled properly, additional cost savings, associated with palliative care could be realized.
Literature
1.
go back to reference Annual Report on the Cause of Death Statistics in (2004) Korea National Statistical Office, Seoul, Korea 2005 Annual Report on the Cause of Death Statistics in (2004) Korea National Statistical Office, Seoul, Korea 2005
2.
go back to reference Kim SG, Hahm MI, Choi KS, Seung NY, Shin HR, Park EC (2008) The economic burden of cancer in Korea in 2002. Eur J Cancer Care (Engl) 17:136–144CrossRef Kim SG, Hahm MI, Choi KS, Seung NY, Shin HR, Park EC (2008) The economic burden of cancer in Korea in 2002. Eur J Cancer Care (Engl) 17:136–144CrossRef
3.
go back to reference Penrod JD, Deb P, Luhrs C et al (2006) Cost and utilization outcomes of patients receiving hospital-based palliative care consultation. J Palliat Med 9:855–860PubMedCrossRef Penrod JD, Deb P, Luhrs C et al (2006) Cost and utilization outcomes of patients receiving hospital-based palliative care consultation. J Palliat Med 9:855–860PubMedCrossRef
4.
go back to reference Annual Report on the Cause of Death Statistics in 2006. Korea National Statistical Office, Seoul, Korea 2005 2007. Annual Report on the Cause of Death Statistics in 2006. Korea National Statistical Office, Seoul, Korea 2005 2007.
5.
go back to reference Fine RL (2004) The imperative for hospital-based palliative care: patient, institutional, and societal benefits. Proc (Bayl Univ Med Cent) 17:259–264 Fine RL (2004) The imperative for hospital-based palliative care: patient, institutional, and societal benefits. Proc (Bayl Univ Med Cent) 17:259–264
6.
go back to reference Oh DY, Kim JE, Lee CH et al (2004) Discrepancies among patients, family members, and physicians in Korea in terms of values regarding the withholding of treatment from patients with terminal malignancies. Cancer 100:1961–1966PubMedCrossRef Oh DY, Kim JE, Lee CH et al (2004) Discrepancies among patients, family members, and physicians in Korea in terms of values regarding the withholding of treatment from patients with terminal malignancies. Cancer 100:1961–1966PubMedCrossRef
7.
go back to reference Yun YH, Lee MK, Chang YJ et al (2009) The life-sustaining treatments among cancer patients at end of life and the caregiver's experience and perspectives. Support Care Cancer 18:189–196PubMedCrossRef Yun YH, Lee MK, Chang YJ et al (2009) The life-sustaining treatments among cancer patients at end of life and the caregiver's experience and perspectives. Support Care Cancer 18:189–196PubMedCrossRef
8.
go back to reference Yun YH, Lee CG, Kim SY et al (2004) The attitudes of cancer patients and their families toward the disclosure of terminal illness. J Clin Oncol 22:307–314PubMedCrossRef Yun YH, Lee CG, Kim SY et al (2004) The attitudes of cancer patients and their families toward the disclosure of terminal illness. J Clin Oncol 22:307–314PubMedCrossRef
9.
go back to reference Winkler EC, Reiter-Theil S, Lange-Riess D, Schmahl-Menges N, Hiddemann W (2009) Patient involvement in decisions to limit treatment: the crucial role of agreement between physician and patient. J Clin Oncol 27:2225–2230PubMedCrossRef Winkler EC, Reiter-Theil S, Lange-Riess D, Schmahl-Menges N, Hiddemann W (2009) Patient involvement in decisions to limit treatment: the crucial role of agreement between physician and patient. J Clin Oncol 27:2225–2230PubMedCrossRef
10.
go back to reference Holroyd EE (2003) Chinese family obligations toward chronically ill elderly members: comparing caregivers in Beijing and Hong Kong. Qual Health Res 13:302–318PubMedCrossRef Holroyd EE (2003) Chinese family obligations toward chronically ill elderly members: comparing caregivers in Beijing and Hong Kong. Qual Health Res 13:302–318PubMedCrossRef
11.
go back to reference Tang ST, Liu TW, Lai MS, Liu LN, Chen CH (2005) Concordance of preferences for end-of-life care between terminally ill cancer patients and their family caregivers in Taiwan. J Pain Symptom Manage 30:510–518PubMedCrossRef Tang ST, Liu TW, Lai MS, Liu LN, Chen CH (2005) Concordance of preferences for end-of-life care between terminally ill cancer patients and their family caregivers in Taiwan. J Pain Symptom Manage 30:510–518PubMedCrossRef
12.
go back to reference Park NR, Yun YH, Shin S, Jeong EK (1999) Medical enpenses during the last 6 months of life in cancer patients. Journal Korean Society Hospice Palliative Care 2:109–113 Park NR, Yun YH, Shin S, Jeong EK (1999) Medical enpenses during the last 6 months of life in cancer patients. Journal Korean Society Hospice Palliative Care 2:109–113
13.
go back to reference Earle CC, Venditti LN, Neumann PJ et al (2000) Who gets chemotherapy for metastatic lung cancer? Chest 117:1239–1246PubMedCrossRef Earle CC, Venditti LN, Neumann PJ et al (2000) Who gets chemotherapy for metastatic lung cancer? Chest 117:1239–1246PubMedCrossRef
14.
go back to reference Matsuyama R, Reddy S, Smith TJ (2006) Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 24:3490–3496PubMedCrossRef Matsuyama R, Reddy S, Smith TJ (2006) Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 24:3490–3496PubMedCrossRef
15.
go back to reference Smith TJ, Cassel JB (2009) Cost and non-clinical outcomes of palliative care. J Pain Symptom Manage 38:32–44PubMedCrossRef Smith TJ, Cassel JB (2009) Cost and non-clinical outcomes of palliative care. J Pain Symptom Manage 38:32–44PubMedCrossRef
16.
go back to reference Lo JC (2002) The impact of hospices on health care expenditures–the case of Taiwan. Soc Sci Med 54:981–991PubMedCrossRef Lo JC (2002) The impact of hospices on health care expenditures–the case of Taiwan. Soc Sci Med 54:981–991PubMedCrossRef
Metadata
Title
Health economics of a palliative care unit for terminal cancer patients: a retrospective cohort study
Authors
Hyun-myung Jung
Jinhyun Kim
Dae Seog Heo
Sun Kyung Baek
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 1/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-010-1047-y

Other articles of this Issue 1/2012

Supportive Care in Cancer 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine